Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Carbonyl Reductase 1 Plays a Significant Role in Converting Doxorubicin to Cardiotoxic Doxorubicinol in Mouse Liver, but the Majority of the Doxorubicinol-Forming Activity Remains Unidentified.

Breysse DH, Boone RM, Long CM, Merrill ME, Schaupp CM, White CC, Kavanagh TJ, Schmidt EE, Merrill GF.

Drug Metab Dispos. 2020 Mar;48(3):187-197. doi: 10.1124/dmd.119.089326. Epub 2020 Jan 18.

PMID:
31955137
2.

Kinetics of Glutathione Depletion and Antioxidant Gene Expression as Indicators of Chemical Modes of Action Assessed in Vitro in Mouse Hepatocytes with Enhanced Glutathione Synthesis.

Melnikov F, Botta D, White CC, Schmuck SC, Winfough M, Schaupp CM, Gallagher EP, Brooks BW, Williams ES, Coish P, Anastas PT, Voutchkova-Kostal A, Kostal J, Kavanagh TJ.

Chem Res Toxicol. 2019 Mar 18;32(3):421-436. doi: 10.1021/acs.chemrestox.8b00259. Epub 2019 Jan 7.

PMID:
30547568
3.

Metabolism of doxorubicin to the cardiotoxic metabolite doxorubicinol is increased in a mouse model of chronic glutathione deficiency: A potential role for carbonyl reductase 3.

Schaupp CM, White CC, Merrill GF, Kavanagh TJ.

Chem Biol Interact. 2015 Jun 5;234:154-61. doi: 10.1016/j.cbi.2014.11.010. Epub 2014 Nov 21.

4.

Functional kinomics identifies candidate therapeutic targets in head and neck cancer.

Moser R, Xu C, Kao M, Annis J, Lerma LA, Schaupp CM, Gurley KE, Jang IS, Biktasova A, Yarbrough WG, Margolin AA, Grandori C, Kemp CJ, Méndez E.

Clin Cancer Res. 2014 Aug 15;20(16):4274-88. doi: 10.1158/1078-0432.CCR-13-2858.

5.

In vivo approaches to assessing the toxicity of quantum dots.

Scoville DK, Schaupp CM, Baneyx F, Kavanagh TJ.

Methods Mol Biol. 2014;1199:179-90. doi: 10.1007/978-1-4939-1280-3_14.

PMID:
25103809
6.

Of mice, rats, and men: could Nrf2 activation protect against aflatoxin heptocarcinogenesis in humans?

Eaton DL, Schaupp CM.

Cancer Prev Res (Phila). 2014 Jul;7(7):653-7. doi: 10.1158/1940-6207.CAPR-14-0119. Epub 2014 Jun 16.

Supplemental Content

Loading ...
Support Center